These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 10150182

  • 21. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
    Marci M, Albiani B, Ricci M, Russo F.
    Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
    [Abstract] [Full Text] [Related]

  • 22. Peripheral arterial disease: drug therapy.
    Schwartz JB.
    J Gend Specif Med; 2002 Mar; 5(4):16-20. PubMed ID: 12192882
    [No Abstract] [Full Text] [Related]

  • 23. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial.
    Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L, Pola R, Santoliquido A, Serricchio M, Tondi P, Nolfe G.
    Drugs Exp Clin Res; 1999 Mar; 25(1):29-36. PubMed ID: 10337502
    [Abstract] [Full Text] [Related]

  • 24. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
    Brass EP, Anthony R, Cobb FR, Koda I, Jiao J, Hiatt WR.
    J Am Coll Cardiol; 2006 Dec 19; 48(12):2539-45. PubMed ID: 17174195
    [Abstract] [Full Text] [Related]

  • 25. Supervised exercise training combined with ginkgo biloba treatment for patients with peripheral arterial disease.
    Wang J, Zhou S, Bronks R, Graham J, Myers S.
    Clin Rehabil; 2007 Jul 19; 21(7):579-86. PubMed ID: 17702699
    [Abstract] [Full Text] [Related]

  • 26. [Drug therapy in peripheral arterial occlusive disease].
    Bollinger A.
    Schweiz Med Wochenschr; 1988 Sep 10; 118(36):1283-9. PubMed ID: 3051339
    [Abstract] [Full Text] [Related]

  • 27. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease.
    Strano A, Hoppensteadt D, Walenga JM, Fareed J, Sabbá C, Berardi E, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Del Guercio M, Pinto A, Alletto G, Nazzari M, Ferrari PA.
    Semin Thromb Hemost; 1996 Sep 10; 22 Suppl 1():35-40. PubMed ID: 8807727
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [The clinico-instrumental evaluation of the efficacy of picotamide in treating chronic obstructive arteriopathies of the lower extremities].
    Canonico V, Ammaturo V, Guarini P, Tedeschi C, Nunziata G, Nappi A, Forgione L, Rengo F.
    Minerva Cardioangiol; 1991 Mar 10; 39(3):75-80. PubMed ID: 1881558
    [Abstract] [Full Text] [Related]

  • 32. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
    Mohler ER, Hiatt WR, Creager MA.
    Circulation; 2003 Sep 23; 108(12):1481-6. PubMed ID: 12952839
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Triflusal in the treatment of patients with chronic peripheral arteriopathy: multicentre double-blind clinical study vs placebo.
    Auteri A, Angaroni A, Borgatti E, Catalano M, De Vizzi GB, Forconi S, Fossati L, Girardello R, Ambrosoli L, Poli A.
    Int J Clin Pharmacol Res; 1995 Sep 23; 15(2):57-63. PubMed ID: 8593974
    [Abstract] [Full Text] [Related]

  • 36. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P, Migliacci R, Arosio E, Bonizzoni E, Minuz P, Violi F, NCX 4016-X-208 Study Group.
    J Vasc Surg; 2012 Dec 23; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [Abstract] [Full Text] [Related]

  • 37. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
    MMW Fortschr Med; 2003 Dec 18; 145(51-52):41. PubMed ID: 14974333
    [No Abstract] [Full Text] [Related]

  • 38. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
    Castaño G, Más R, Roca J, Fernández L, Illnait J, Fernández JC, Selman E.
    Angiology; 1999 Feb 18; 50(2):123-30. PubMed ID: 10063942
    [Abstract] [Full Text] [Related]

  • 39. Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease.
    Allegra C, Antignani PL, Schachter I, Koverech A, Messano M, Virmani A.
    Ann Vasc Surg; 2008 Feb 18; 22(4):552-8. PubMed ID: 18502605
    [Abstract] [Full Text] [Related]

  • 40. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J, Young IS, Lee B, Soong CV.
    Eur J Vasc Endovasc Surg; 2009 Mar 18; 37(3):326-35. PubMed ID: 19112032
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.